CYP2C9*2 and *3
<p>Polymorphisms of <em>CYP2C9*2</em>, <em>CYP2C9*3</em> and <em>VKORC1</em> genes related to time in therapeutic range in patients with atrial fibrillation using warfarin</p>
9
CYP2C9 ) and response ( VKORC1 ) have an
315
<p>The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy</p>
8
Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
8
Investigating the role of plasma glucose concentration as a phenotypic marker for CYP2C9 genetic variants, in the diabetic population of Gujarat
6
CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
8
Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus
7
Genetic Polymorphisms of CYP2C9: Comparison of Prevalence in the Lebanese Population with Other Populations
6
Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy
7
Vol 8, No 4 (2016)
12
Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with <em>CYP2C8*3</em> and <em>CYP2C9</em>
9
Download Download PDF
8
CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement
8
Cytochrome P450 genetic variants and hypertension risk in South Indian population
5
2 (3 Chlorophenyl) 4 (2 hydroxyethyl) 3 methylmorpholin 2 ol monohydrate
7
(Z) 2 Thiophen 3 ylmethylene 1 aza bicyclo[2 2 2]octan 3 one
7
Methyl 3 (2 chloro 5 ethyl 3 pyridyl) 3 hydroxy 2 methylenepropanoate
7
N (3 Chlorophenyl) 2 cyano 3 (4 hydroxy 3 methoxy 2 nitrophenyl)prop 2 enamide
7
(Z) 3 Chloro N [(Z) 3 (3 chloro 2 methylphenylimino)butan 2 ylidene] 2 methylaniline
5
N′ (3 Ethoxy 2 hydroxybenzylidene) 3 hydroxynaphthalene 2 carbohydrazide
7